Despite $30-40 billion in enterprise investment into GenAI so far, “95% of organizations are seeing zero return.” Boards want ...

Sanger sequencing is the unsung workhorse of molecular biology, one whose value has long been undermined by the tedious nature of processing its data. Converting files of raw sequencing data into a ...